A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Matthews, Lynn T ^a   Giddy, Janet ^b   Ghebremichael, Musie ^c   Hampton, Jane ^b   Guarino, Anthony J ^d   Ewusi, Aba ^e   Carver, Emma ^f   Axten, Karen ^c   Geary, Meghan C ^g   Gandhi, Rajesh T ^c,h   Bangsberg, David R ^c,h,i  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MCCORD HOSPITAL   (South Africa)

^c HARVARD UNIVERSITY   (United States)

^d MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

^e HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g ALBANY MEDICAL COLLEGE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; LACTIC ACID;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROTECTION; RISK FACTOR; SEX DIFFERENCE; BLOOD; CELL DEATH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; KAPLAN MEIER METHOD; MITOCHONDRION; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACIDOSIS, LACTIC; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CELL DEATH; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LACTIC ACID; MALE; MITOCHONDRIA; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79954548548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018736     Document Type: Article

References (29)

1. Lactic Acidosis International Study Group (2007) Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 21: 2455-2464.
2. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, et al. (2006) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43: 645-653.
3. Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, et al. (2006) Understanding and avoiding antiretroviral adverse events. Current Pharmaceutical Design 12: 1075-1090.
4. Bolhaar MG, Karstaedt AS, (2007) A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 45: 254-260.
5. Boubaker KMF, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave J.-P, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A, (2001) Hyperlactatemia and antiretroviral therapy: The Swiss HIV cohort study. Clin Infect Dis 33: 1931.
6. Fabian J, Venter WD, Mkhabela L, Levin JB, Baker L, et al. (2008) Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience. S Afr Med J 98: 795-800.
7. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, et al. (2006) A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 96: 722-724.
8. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, et al. (2008) Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health (Larchmt) 17: 1471-1475.
9. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, et al. (2002) Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. Aids 16: 1341-1349.
10. Stead D, Osler M, Boulle A, Rebe K, Meintjes G, (2008) Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther 13: 937-943.
11. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, et al. (2007) Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 46: 318-322.
12. Stenzel MS, Carpenter CC, (2000) The management of the clinical complications of antiretroviral therapy. Infect Dis Clin North Am 14: 851-878, vi.
13. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision Geneva World Health Organization.
14. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT, (2007) Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 196 (Suppl 3): S449-456.
15. Rosen S, Long L, Fox M, Sanne I, (2008) Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 48: 334-344.
16. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, et al. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 104: 148-153.
17. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, et al. (2007) Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12: 753-760.
18. Osler M, Stead D, Rebe K, Meintjes G, Boulle A, (2009) Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 11: 121-129.
19. Lonergan JT, Barber RE, Mathews WC, (2003) Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 17: 2495-2499.
20. Adult AIDS Clinical Trial Group (2003) AACTG toxicity evaluation group, Chair Rob Murphy.
21. Ivers LC, Mukherjee JS, (2006) Point of care testing for antiretroviral therapy-related lactic acidosis in resource-poor settings. AIDS 20: 779-780.
22. Kiragga AK, Ocama P, Reynolds SJ, Kambugu A, Ojiambo H, et al. (2008) Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 49: 564-566.
23. Cox D, Snell E, (1989) Analysis of Binary Data, 2nd Edition London Chapman and Hall.
24. Harrell FE Jr, (2001) Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis New York Springer-Verlag.
25. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. (2007) Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opinion in Phamacotherapy 8.
26. Bellomo R, (2002) Bench-to-bedside review: lactate and the kidney. Crit Care 6: 322-326.
27. Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, et al. (2003) Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 36: 1324-1328.
28. Spaulding A, Rutherford GW, Siegfried N, Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev pp. CD008651.
29. South African National AIDS Council (2010) The South African Antiretroviral Treatment Guidelines Department of Health; Republic of South Africa.